Dogwood Therapeutics: Halneuron Giai đoạn 2b CINP kết quả sơ bộ mùa thu 2026

The 8-K confirms the Halneuron Phase 2b trial in chemotherapy-induced neuropathic pain remains on track with 164 patients enrolled and top-line results guided for fall 2026. Separately, the FDA accepted the SP16 IND for a Phase 1b CIPPN study that will begin enrolling mid-2026.

Thông tin chính

Nộp lúc: 12:50 14 thg 5, 2026
Sự kiện: Kết quả topline
Chiều hướng: Trung lập
Công ty: DWTXDogwood Therapeutics
Tài sản: Halneuron
Nguồn: SEC 8-K
Độ tin cậy: Có nguồn
bệnh nhân đã đăng ký: 164

Trích đoạn nguồn

EX-99.1 2 dwtx-20260514xex99d1.htm EX-99.1 Exhibit 99.1 Dogwood Therapeutics Announces First Quarter 2026 Financial Results - Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 - - FDA acceptance of SP16 Investigational New Drug Application for the treatment of Chemotherapy Induced Pain and Neuropathy – - Announces Worldwide Development and Commercialization Partnership for Legacy Antiviral Assets with potential value up to $100M to Dogwood and its current and former shareholders - ALPHARETTA, Ga., May 14, 2026 -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced financial results for the

SEC 8-K